secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entera Bio Ltd. (ENTXW)
CIK:        0001638097
Form:       8-K
Filed at:   2023-08-11T23:59:59+00:00
Accession:  0001178913-23-002832
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entera Bio reports H1 net loss $4.5M, cash $9.1M; updates on EB613 and EB612 trials
--------------------------------------------------------------------------------

- H1 2023 net loss $4.5M ($0.16/share) vs $7.0M ($0.24) in H1 2022.
- Cash and equivalents $9.1M expected to fund operations into Q3 2024.
- R&D expenses $2.1M (down 32% YoY); G&A $2.4M (down 41% YoY).
- EB613 Phase 3 initiation depends on FDA review of FNIH-ASBMR SABRE BQP qualification.
- Phase 1B study of next-gen EB612 platform (45 subjects, 3 cohorts) started May 2023; H2 2023 data readout expected.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/0001178913-23-002832-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638097/000117891323002832/zk2330154.htm
  HTML page:      https://secwatch.observer/filing/0001178913-23-002832

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer